10x Genomics, Inc. (TXG)

10x Genomics developed from a single founding insight: that cells in a tissue sample could be individually analyzed and their gene expression profiles captured on a massive scale if engineered correctly. The company was founded in 2012 by Sergi Hochmann and a team of Stanford engineers who saw an opportunity to build instruments and reagents for single-cell genomics when the technology was still nascent and mostly academic. Two decades later, 10x Genomics has become the leading supplier of tools for single-cell analysis to researchers and clinicians worldwide.

The founding insight and the technology

The conventional approach to studying gene expression in a tissue sample was to homogenize the tissue, extract RNA, and measure it in bulk. This approach lost crucial information: you learned the average gene-expression profile of billions of mixed cells, but you could not distinguish which genes were active in which cell types. If a tissue contained cancerous cells mixed with normal cells, bulk analysis would average them together and obscure the differences.

Sergi Hochmann and the 10x founding team saw a solution: use microfluidics — tiny channels and chambers designed to handle individual cells — to separate cells from a tissue sample, capture their RNA, and sequence each cell’s transcriptome individually. The technical challenge was enormous: capturing cells one at a time without damaging them, ensuring you got representative sampling, and processing millions of cells cost-effectively.

The insight that made 10x viable was using oil-in-water emulsions and barcoded beads. A cell suspension is mixed with barcoded beads in oil, creating millions of tiny droplets. Each droplet typically contains one cell and one bead. The bead’s barcode uniquely labels all RNA captured within that droplet, allowing millions of cells to be processed in a single reaction. The RNA is then sequenced, and because each RNA molecule carries a barcode, you can tell which cells its sequences came from. This was revolutionary because it allowed researchers to process hundreds of thousands of cells per experiment at a cost that made large-scale experiments feasible.

Product development and market expansion

10x Genomics’ first commercial product was the Chromium Single-Cell platform, launched in the mid-2010s. It was adopted quickly by academic researchers and pharmaceutical companies developing new therapies, because single-cell sequencing revealed cell types and gene-expression states invisible to bulk analysis. Oncology researchers could isolate and profile cancer cells within tumors. Immunologists could characterize immune-cell populations. Developmental biologists could trace gene-expression changes as tissues formed.

The success of Chromium validated the market and attracted competitors, but 10x’s platform advantages — high cell recovery, low cost per cell, and integrated workflow software — gave it a large installed base. As the platform matured, the company expanded the product line. Spatial transcriptomics — a category that captures gene expression while preserving the physical location of cells within a tissue section — became a major growth area. The Visium platform measures thousands of genes across a tissue slice, mapping which genes are active in which anatomical regions.

10x also developed platforms for whole-genome sequencing, V(D)J sequencing for immune repertoires (the collection of antibodies and T-cell receptors a person or tissue carries), and eventually for high-resolution protein detection on cells alongside RNA. Each product extension widened the company’s addressable market and deepened its stickiness with existing customers.

The path to profitability and public markets

10x remained a private company through much of the 2010s, funded by venture capital and expanding its manufacturing, sales, and customer-support infrastructure. The company was solidly cash-generative — selling instruments and consumables is a recurring-revenue model, because researchers must buy new beads and reagents for every experiment — but it reinvested heavily in R&D and capacity.

The company went public in 2021, raising capital to fund further product development and international expansion. The IPO coincided with peak enthusiasm for genomics and precision medicine in financial markets. The stock soared, then declined through 2022 and 2023 as growth slowed and the broader market repriced genomics companies.

The slowdown reflected several factors: some laboratories had built up consumable inventory during the pandemic, delaying repeat purchases; adoption growth in academic research began to plateau as the installed base matured; and pharmaceutical customers delayed research spending in anticipation of economic headwinds. These are cyclical pressures typical of research-tool companies, but they created a gap between the market’s peak expectations and 10x’s actual growth rate.

The business model and the installed base

10x Genomics generates revenue from two sources: instruments and consumables. Instruments — Chromium and Visium systems — are capital equipment that laboratories purchase and use for years. The margins on instruments are moderate but the real business is consumables. Every experiment requires new beads, reagents, and assay kits. A laboratory with an installed base of instruments becomes a predictable source of recurring consumable revenue.

This model is typical of research-tool companies and is highly profitable at scale. Once an instrument is installed and a customer is trained, they continue to buy consumables with minimal sales friction. The recurring revenue stream is difficult for competitors to disrupt and produces strong operating leverage — each additional consumable sale requires minimal additional cost.

10x’s competitive position rests on the quality and breadth of its product line, the size of its installed base of instruments, and the technical and analytical software that helps customers interpret results. Competitors have emerged — including players from larger companies like Illumina — but 10x remains the market leader in single-cell RNA sequencing and has extended that lead into spatial transcriptomics and protein detection.

The research landscape and future demand

Single-cell genomics has become mainstream in life-sciences research. University departments, research hospitals, and pharmaceutical companies now treat single-cell sequencing as a routine technique rather than a novelty. This mainstreaming is both positive and challenging for 10x: positive because demand is large and likely to grow; challenging because competition has arrived and the technology is being commoditized.

The near-term growth drivers for 10x include continued adoption in clinical diagnostics (using single-cell analysis for disease diagnosis and treatment selection), expansion in cell therapy development, and growth in international markets where 10x penetration remains low. Longer-term, the question is whether 10x’s platforms will remain sufficiently differentiated to maintain pricing power and margins as the field matures and alternatives proliferate.

10x has also pursued strategic acquisitions and partnerships to expand beyond pure sequencing into adjacent areas like cell imaging and culture. These moves attempt to position the company as a broader supplier of tools for cellular analysis rather than a narrower single-cell genomics company.

How to research 10x Genomics

Start with 10x’s annual 10-K (SEC CIK 0001770787) and quarterly 10-Q filings, which break out revenue by geography and by product category (instruments versus consumables). Watch for instrument placements — the number of new Chromium and Visium systems sold each quarter — because this drives the installed base and thus future consumable revenue.

Pay attention to growth rates by customer segment: academic research, pharmaceutical and biotech companies, and clinical diagnostics are the main buckets, and growth rates differ. Note the company’s gross-margin trend, especially for consumables, which should be stable or expanding if the business is healthy. Track the level of R&D spending as a percentage of revenue; if 10x is investing heavily in new products, it signals confidence in future growth but also competitive intensity.

Understand the competitive landscape: who is entering single-cell sequencing and spatial transcriptomics, and how are they differentiated? Watch for regulatory approvals or clinical-diagnostic validation, which would unlock a large new revenue stream if 10x can demonstrate utility in clinical decision-making. Finally, understand the technical trends in genomics research — what questions researchers are trying to answer and whether 10x’s tools are becoming more or less central to answering them. The company’s success ultimately depends on remaining the tool of choice as the field evolves.